465 related articles for article (PubMed ID: 26338063)
1. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
[TBL] [Abstract][Full Text] [Related]
5. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
7. [Progression of diagnosis and treatment of medullary thyroid carcinoma].
Wang X; Li C; Huang L; Shui CY; Liu W; Cai YC; Sun RH; Zhou YQ; Jiang J; Wang W; Zeng DF
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Apr; 54(4):306-310. PubMed ID: 30991785
[No Abstract] [Full Text] [Related]
8. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
9. Medullary thyroid carcinoma.
Leboulleux S; Baudin E; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
[TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
11. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
12. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
14. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T; Machlah YM; Führer D
Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
[TBL] [Abstract][Full Text] [Related]
15. Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958
[TBL] [Abstract][Full Text] [Related]
16. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma.
Alapat DV; Ain KB; Sloan DA; Monaghan KG; Karabakhtsian RG
Endocrine; 2011 Apr; 39(2):148-52. PubMed ID: 21243446
[TBL] [Abstract][Full Text] [Related]
17. Hereditary Medullary Thyroid Cancer Genotype-Phenotype Correlation.
Frank-Raue K; Raue F
Recent Results Cancer Res; 2015; 204():139-56. PubMed ID: 26494387
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
19. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
20. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
Trimboli P; Giovanella L
Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
